Navigation Links
Illustris Launches Novel Technology And Announces Veteran Industry Leadership
Date:3/1/2017

PALO ALTO, Calif., March 1, 2017 /PRNewswire/ -- Illustris Pharmaceuticals, Inc. today announced the formation of its leadership team to launch its revolutionary delivery technology platform.  The leadership team consists of Jonah Shacknai, former CEO of Medicis, Mark Prygocki, former President of Medicis, Dr. Jacob Waugh, Co-Founder Revance, Dr. S. K. Tan, founding member of Derma-Rx and IDS Clinic and one of the foremost physicians in aesthetics and cosmeceuticals in Asia, and Andrew Hirschberg, a 25 year veteran of pharmaceutical industry investment banking. This experienced management team will focus on licensing opportunities for companies seeking to enable or optimize the delivery of their active ingredients through tissue structures such as skin, eyes and mucosal surfaces.

"We are pleased to have assembled a world-class leadership team to introduce Illustris' innovative delivery technology," said Jonah Shacknai, Chairman of Illustris. "We believe the Illustris family of technologies provides a significant competitive advantage with its novel approach to molecule delivery, yielding enhanced safety and efficacy for patients.  We are eager to introduce the Illustris technology to the wider industry, and showcase its significant advantages over current delivery platforms."

The Illustris technology platform both enables the delivery of large molecules (up to 160KD) through tissue structures and optimizes the absorption of compounds typically delivered through skin, eyes and mucosal surfaces. The Illustris technology platform facilitates the delivery of active ingredients through tissue structures by deploying decoys, many of which temporarily distract and relax anchors that bind tissue cells together, providing a portal for active ingredients to permeate the targeted site.  Based on the clinical objective, Illustris can deploy the appropriate amount of decoy to fully penetrate or partially permeate the targeted tissue structure or organ system. The Illustris proprietary platform enables the delivery through tissue structures of macromolecule active ingredients (up to 160KD) which are historically difficult or impossible to deliver topically, and optimizes delivery of active ingredients which previously permeated tissue structures inefficiently. Illustris has filed broad patent applications across several classes of applications and compounds.

About Illustris

Illustris is a privately held bio-development company specializing in its proprietary delivery technology. The Illustris delivery technology both enables the delivery of large molecules through tissue structures and optimizes the absorption of compounds typically delivered through skin, eyes and mucosal surfaces.

For more information about Illustris, please visit the Company's website at www.Illustris.com.

CONTACT:
Illustris Pharmaceuticals, Inc.
(650) 334-2090

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/illustris-launches-novel-technology-and-announces-veteran-industry-leadership-300415665.html


'/>"/>
SOURCE Illustris Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Darrow Wealth Management Launches New Website
2. Guidepoint Global Launches Two Major Enhancements to its Client Research Portal
3. Elsevier Launches PracticeUpdate, a Free Information Portal for Physicians
4. Neogen launches rapid tests for ractopamine
5. Rockingham County Economic Development Launches New Website
6. BioHealth Innovation, Inc. Launches Program to Help Life Science Companies Navigate Federal Funding Application Process
7. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
8. Dr. Richard Charmoy Launches Groundbreaking Cavity Prevention Program that Can Lower Tooth Decay Rates by 74%
9. CellHealth Institute Launches with Support from Influential Investors
10. Dr. Timothy Rauch of Albuquerque, New Mexico Launches a Groundbreaking Cavity Prevention Program
11. Neighborhood Smiles Launches a Groundbreaking Cavity Prevention Program for Their Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2019)... BOSTON (PRWEB) , ... January 31, 2019 , ... The ... in Boston this spring to showcase their tools to the largest gathering of ... IBM, DataRobot, SAS, S&P Global and Mathworks are partnering with the Open Data ...
(Date:1/30/2019)... ... January 29, 2019 , ... MabPlex ... (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China and ... by multiple global investors lead by China's State Development & Investment Corporation (SDIC) ...
(Date:1/30/2019)... ... 30, 2019 , ... The Society for Laboratory Automation and ... best practices for laboratory automation and screening. This year the conference will be ... Visikol will be at booth #345 and throughout the conference will highlight its ...
(Date:1/24/2019)... ... January 22, 2019 , ... Dr. Douglas Stramel of Advanced Care Veterinary ... Therapy System (V-PET™) for nearly three years. A proponent of Regenerative Medicine, ... 2007 and began using V-PET™ 2016. V-PET™ is a gravity filtration-based platelet therapy ...
Breaking Biology Technology:
(Date:2/6/2019)... ... February 04, 2019 , ... uBiome, the leader microbial genomics, ... help individuals understand how the gut microbes may increase the risk of arterial ... foods that contain choline and L-carnitine, such as red meat and eggs, various ...
(Date:2/2/2019)... SAN FRANCISCO (PRWEB) , ... January 31, 2019 ... ... the leader in microbial genomics, has awarded microbiome research support in study design, ... Barry Behr, PhD, HCLD, Professor of Obstetrics and Gynecology, and Dr. Sara Vaughn, ...
(Date:1/30/2019)... ... January 30, 2019 , ... ... high-impact life science and biotechnology companies, announced today that it will host ... disease-focused venture funds to discuss their investment philosophies, explain their fund and ...
Breaking Biology News(10 mins):